Automated detection and control of controlled substances
Poster Jan 26, 2015
Joe Bradley, Ian Johns
Chemical and pharmaceutical companies routinely work with controlled substances, and must have adequate controls in place to meet the rapidly changing legislative requirements of the countries in which they operate.
This legislation is becoming increasingly complex and changes frequently as legislators try to keep up with emerging “legal highs”. Meanwhile, externalization of R&D means that compounds are synthesised, stored and transported across a multiplicity of geographies with differing laws.
In 2013 Scitegrity, in conjunction with the Pistoia Alliance and a number of pharmaceutical companies, developed Controlled Substances Squared (CS2) to address this challenge.
The system is able to scan large chemical libraries (millions of compounds) and determine whether a compound is considered as controlled in a country and what controls are needed.
Regulatory T-Cells (Tregs) Within Bone Marrow-Derived Stem Cells (BMSCs) Actively Confer Immunomodulatory and Neuroprotective Effects Against StrokePoster
We found a distinct subpopulation of Tregs within BMSCs. Tregs and BMSCs in co-culture conferred neuroprotection that varied in a dose-dependent manner. Tregs minimized stem cell production of IL-6, a pro-inflammatory cytokine, and inhibited BMSC secretion of FGF-beta, a cytokine related to BMSC proliferation and differentiation. The ratio of Tregs found natively in BMSCs is optimally adapted to provide the maximum neuroprotective benefit of stem cell treatment after ischemic stroke.READ MORE
Internet-Based Biomarker Collection Feasibility: Experiences of a Tobacco Cessation Program for People Living with HIVPoster
This project introduces video-conferencing as a method for biomarker collection in research and will explain how biomarker collection via video-conferencing was implemented in a pilot ehealth intervention.READ MORE
Alterations in Immunophenotype of Autoimmune-prone Hypomorphic RAG-deficient Patients with CID-G/AI PhenotypePoster
Patients with partial deficiency of recombination-activating genes 1 or 2 (RAG1/2) can present with a wide spectrum of primary immunodeficiencies including combined immunodeficiency with granuloma and/or autoimmunity (CID-G/AI). Prior case reports have highlighted alterations in B and T cell compartments; however comprehensive characterization of these cell populations with focus on autoreactive-prone subsets has not been reported.READ MORE
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018